After Stifel Nicolaus and Piper Jaffray gave Argenx Se (NASDAQ: ARGX) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Boris Peaker maintained a Buy rating on Argenx Se today. The company’s shares opened today at $133.29, close to its 52-week high of $135.46.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 6.7% and a 43.9% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and CytomX Therapeutics Inc.
Currently, the analyst consensus on Argenx Se is a Strong Buy with an average price target of $145.83, representing a 9.4% upside. In a report issued on February 22, Guggenheim also initiated coverage with a Buy rating on the stock with a $157 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $135.46 and a one-year low of $63.81. Currently, Argenx Se has an average volume of 222K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
argenx SE is a clinical-stage biotechnology company, which engages in the research and development of human monoclonal antibodies for the treatment of cancer and oncological, autoimmune, and inflammatory diseases. Its products include ARGX-113 for severe autoimmune diseases and ARGX-110 for T-cell lymphoma and acute myeloid leukemia.
